HDAC inhibitors exert complex and multifaceted immunomodulatory effects in a concentration-dependent manner by targeting key immune components in the tumor microenvironment (TME), including the extracellular matrix (ECM), macrophages, T cells, B cells, natural killer cells, and dendritic cells (Figure 2). The gene discussed is HDAC9; the disease is neoplasm.